NCT04510792View on ClinicalTrials.gov

IMpact of HyPeRkalaemia on ThErapy with Renin AngiotenSin AldoSterone System Inhibitors

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

November 3, 2023

Study Completion Date

November 30, 2024

Conditions
Hyperkalemia
Interventions
OTHER

No intervention

No intervention

Trial Locations (1)

PO6 3LY

Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth

Sponsors

Collaborators (1)

Vifor Pharma
All Listed Sponsors
collaborator

Vifor Pharma

INDUSTRY

lead

Portsmouth Hospitals NHS Trust

OTHER_GOV

NCT04510792 - IMpact of HyPeRkalaemia on ThErapy with Renin AngiotenSin AldoSterone System Inhibitors | Biotech Hunter | Biotech Hunter